மண்டி ஃப்யாஹீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from மண்டி ஃப்யாஹீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In மண்டி ஃப்யாஹீ Today - Breaking & Trending Today
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Share this article Share this article BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed s Compensation Committee and made as a material inducement to each employee s entry into employment with the Company. In connection with the commencement of their employment, the employees received options on June 1, 2021 to purchase an aggregate 59,020 shares of Insmed common stock at an exercise price of $25.17 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant. ....
Message : Required fields BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed s Compensation Committee and made as a material inducement to each employee s entry into employment with the Company. In connection with the commencement of their employment, the employees received options on June 1, 2021 to purchase an aggregate 59,020 shares of Insmed common stock at an exercise price of $25.17 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant. ....
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference -Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease- -Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high number needed to harm (NNH)- News provided by Share this article Share this article BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP) at the virtual America ....
Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters Options to Purchase Additional Shares and Notes News provided by Share this article Share this article BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the Equity Offering ) of 11,500,000 shares of its common stock (the Shares ), including 1,500,000 Shares issued pursuant to the exercise in full of the underwriters option to purchase additional Shares, at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and the previously announced registered underwritten public offering (the Notes Offering ) of $575 million aggregate principal amount of its 0.75% convertible senior notes due 2028 (the Notes ), including $75 million aggregate principal amount of Notes purchase ....